Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC.

Fiche publication

Date publication

novembre 2018

Journal

Oncotarget

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BILGER Karin , Pr RUBIO Marie Thérèse

Tous les auteurs :
Bourgeois AL, Labopin M, Leclerc M, de Latour RP, Bourhis JH, Ceballos P, Orvain C, Wallet HL, Bilger K, Blaise D, Rubio MT, Guillaume T, Mohty M, Chevallier P,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30564300

Résumé

Clofarabine has been proved to have higher anti-leukemic myeloid activity compared to fludarabine, a drug extensively used as part of reduced intensity conditioning (RIC) for allogeneic stem cell transplantation (allo-SCT).